← back to search

Celeste Leigh Pearce

University of Michigan · US
Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, COVID-19 and healthcare impacts, Cancer Immunotherapy and Biomarkers, and COVID-19 Clinical Research Studies.
h-index
42
citations
9,338
works
507
NIH funding
primary concept
email

Recent publications

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Journal of Clinical Investigation 2024cited by 17position: lastdoi
Abstract B047: Development and validation of an improved risk stratification model for ovarian cancer
Cancer Research 2024cited by 1position: middledoi
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
JNCI Journal of the National Cancer Institute 2023cited by 25position: middledoi
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility
JAMA Network Open 2023cited by 11position: middledoi
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Clinical Cancer Research 2023cited by 10position: middledoi
A framework for assessing interactions for risk stratification models: the example of ovarian cancer
JNCI Journal of the National Cancer Institute 2023cited by 3position: middledoi
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: middledoi
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Nature Genetics 2022cited by 109position: middledoi
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Cancer 2022cited by 43position: middledoi
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia
Journal of Clinical Oncology 2022cited by 30position: middledoi
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology 2022cited by 26position: middledoi
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Clinical Cancer Research 2022cited by 21position: middledoi
Effects of risk factors for ovarian cancer in women with and without endometriosis
Fertility and Sterility 2022cited by 18position: middledoi
Reproductive Factors Do Not Influence Survival with Ovarian Cancer
2022cited by 2position: last
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2021cited by 23position: middledoi
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Gynecologic Oncology 2021cited by 12position: middledoi
Association Between Breastfeeding and Ovarian Cancer Risk
JAMA Oncology 2020cited by 272position: middledoi
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers
Nature Communications 2020cited by 131position: middledoi
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Clinical Cancer Research 2020cited by 75position: middledoi
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
JNCI Journal of the National Cancer Institute 2020cited by 37position: lastdoi
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer
Epidemiology 2020cited by 33position: lastdoi
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Gynecologic Oncology 2020cited by 28position: lastdoi
Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case–control studies
European Journal of Epidemiology 2020cited by 1position: middledoi
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Nature reviews. Cancer 2019cited by 51position: middledoi
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
International Journal of Epidemiology 2019cited by 40position: middledoi
Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers
bioRxiv (Cold Spring Harbor Laboratory) 2019cited by 30position: middledoi
Identification of novel epithelial ovarian cancer loci in women of African ancestry
International Journal of Cancer 2019cited by 28position: middledoi
Population based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high grade serous ovarian cancer
medRxiv 2019cited by 0position: middledoi
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
International Journal of Cancer 2018cited by 17position: middledoi
Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies
International Journal of Epidemiology 2017cited by 47position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Andrew Berchuck · Duke University7 papers (2015–2024)Penelope M. Webb · QIMR Berghofer Medical Research Institute6 papers (2015–2024)Anna H. Wu · University of Southern California6 papers (2015–2024)Francesmary Modugno · University of Pittsburgh6 papers (2015–2024)Paul D.P. Pharoah · University of Thessaly6 papers (2015–2024)Marc T. Goodman · Cancer Institute of New South Wales5 papers (2020–2024)Malcolm C. Pike · Kettering University5 papers (2015–2024)Jennifer A. Doherty · University of Utah5 papers (2015–2024)Joellen M. Schildkraut · Institute of Biomedical Sciences, Academia Sinica4 papers (2015–2023)Usha Menon · Amrita Institute of Medical Sciences and Research Centre4 papers (2015–2023)Alice W. Lee · California State University, Fullerton4 papers (2015–2024)Harvey A. Risch · Dana-Farber Cancer Institute3 papers (2020–2022)Elisa V. Bandera · Rutgers, The State University of New Jersey3 papers (2020–2024)Britton Trabert · University of Utah3 papers (2022–2024)Susan J. Ramus · Cancer Institute of New South Wales3 papers (2019–2023)Kathryn L. Terry · Brigham and Women's Hospital3 papers (2022–2024)Kirsten B. Moysich · Dartmouth College3 papers (2020–2023)Susan J. Jordan · The University of Queensland3 papers (2020–2023)Minh Tung Phung · University of Michigan–Ann Arbor3 papers (2022–2024)Hoda Anton‐Culver · University of California, Irvine3 papers (2022–2024)